Equip Your Preclinical I/O Studies with Robust Models to Enable Enhanced Clinical Relevancy & Translatability
As the only industry-focused meeting dedicated to preclinical scientists and translational oncologists in the immunotherapy space, the PREDiCT Series is once again delighted to bring to you Tumor Models San Francisco 2021, albeit with a new name.
Running in a digital capacity this year, the 5th PREDiCT: Tumor Models for Immuno-Oncology 2021 Summit enables you to discover the latest I/O preclinical strategies in the biopharmaceutical industry, evaluate & debate next-generation preclinical models for immuno-oncology studies and form high-quality connections to ensure cooperation and collaboration stays alive in a socially-distant world.
Offering a wide range of content-driven presentations, expert-led Q&A and discussion, interactive workshops, and the provision of networking opportunity, benchmark against your fellow colleagues to advance your I/O candidates towards the clinic.
Download the full program for more information on sessions and the expert speaker faculty.
"This was a great conference for staying on top of some of the latest developments in IO models and getting a better understanding of the various models, their utility and limitations. The size of the conference allows for many fruitful discussions and ease of meeting with several of the major CROs that provide models for those in the immuno-oncology space."
Michael Mattie, Associate Director, Translational Medicine, Kite Pharma
Expert Speakers at the 2021 PREDiCT: Tumor Models for Immuno-Oncology Summit include:
Senior Director - Innovation & Product Development at JMCRS
The Jackson Laboratory
Director – In Vivo Pharmacology
Professor – Neurosurgery & Cell Developmental Biology
University of Michigan
Executive Director - Scientific Development